Siegal T
Neuro-Oncology Clinic, Hadassah Hebrew University Hospital, Jerusalem, Israel.
J Neurooncol. 1998 Jun-Jul;38(2-3):151-7. doi: 10.1023/a:1005999228846.
Malignant subarachnoid deposits complicate both primary central nervous system (CNS) tumors and systemic neoplasms. Although the pathophysiology of symptoms and signs can not be separated by the category of primary tumors that seeds the leptomeninges, the approach to therapy is not similar in primary CNS tumors and in systemic neoplasms. Standard therapy for subarachnoid seeding in primary CNS tumors include conventional or high doses of systemic chemotherapy with various combinations of radiotherapy given either to limited fields or to the whole neuroaxis. Direct administration of chemotherapy to the CSF is not being used. In contrast, whenever a systemic tumor seeds the subarachnoid space the standard approach includes intensive intra-CSF chemotherapy, radiotherapy to limited or extended CNS fields and various combinations of systemic chemotherapy. The published experience with the conventional therapy is reviewed and is critically analyzed. Evidence indicating that high dose systemic chemotherapy can replace intra-CSF treatment in some subgroups are also reviewed and the rationale for this approach is specified. Recent experience in which intra-CSF therapy was prospectively eliminated from the treatment protocol of leptomeningeal metastases of solid tumors reveals that the response rate and survival are similar to those obtained by protocols that differed only by the inclusion of intra-CSF chemotherapy. Patients who were treated by radiotherapy alone combined with systemic chemotherapy but without the intra-CSF therapy were spared the high rate of early and delayed complications directly related to intra-CSF therapy. Still, treatment outcome did not differ. Therefore, future research efforts and prospective clinical trials should investigate the best chemotherapeutic schedules and their sequencing with radiotherapy or with more intensive complementary systemic chemotherapy schemes. Newly designed drugs with long circulation time and improved CNS penetration may serve for this purpose.
恶性蛛网膜下腔转移可使原发性中枢神经系统(CNS)肿瘤和全身性肿瘤病情复杂化。尽管症状和体征的病理生理学不能根据软脑膜播散的原发性肿瘤类别来区分,但原发性CNS肿瘤和全身性肿瘤的治疗方法并不相同。原发性CNS肿瘤蛛网膜下腔播散的标准治疗包括常规或高剂量全身化疗,并联合对有限区域或整个神经轴进行不同组合的放疗。目前未采用向脑脊液直接给药化疗的方法。相比之下,当全身性肿瘤播散至蛛网膜下腔时,标准治疗方法包括强化脑脊液内化疗、对有限或扩大的CNS区域进行放疗以及多种全身性化疗组合。本文回顾并批判性分析了传统治疗方法的已发表经验。文中还回顾了表明高剂量全身化疗可在某些亚组中替代脑脊液内治疗的证据,并明确了这种治疗方法的基本原理。最近一项前瞻性地从实体瘤软脑膜转移治疗方案中取消脑脊液内治疗的研究发现,其缓解率和生存率与仅因包含脑脊液内化疗而不同的方案所获得的结果相似。接受单纯放疗联合全身化疗但未进行脑脊液内治疗的患者避免了与脑脊液内治疗直接相关的高比例早期和延迟并发症。然而,治疗结果并无差异。因此,未来的研究工作和前瞻性临床试验应探索最佳化疗方案及其与放疗或更强化的辅助全身化疗方案的联合顺序。具有长循环时间和改善的CNS渗透性的新设计药物可能适用于此目的。